E7389 in Treating Patients With Advanced Solid Tumors
Completed
National Cancer Institute (NCI)
Phase 1
2002-08-01
Phase I trial to study the effectiveness of E7389 in treating patients who have advanced
solid tumors. Drugs used in chemotherapy use different ways to stop tumor cells from dividing
so they stop growing or die
Eribulin Mesylate in Treating Patients With Recurrent Ovarian Epithelial, Primary Peritoneal Cavity, or Fallopian Tube Cancer
Completed
National Cancer Institute (NCI)
Phase 2
2006-04-01
This phase II trial is studying how well eribulin mesylate works in treating patients with
recurrent ovarian epithelial, primary peritoneal cavity, or fallopian tube cancer. Drugs used
in chemotherapy, such as eribulin mesylate, work in different ways to stop the growth of
tumor cells, either by killing the cells or by stopping them from dividing.
Eribulin Mesylate in Treating Patients With Metastatic Prostate Cancer That Did Not Respond to Hormone Therapy
Completed
National Cancer Institute (NCI)
Phase 2
2006-11-01
This phase II trial is studying how well eribulin mesylate (E7389; Halichondrin B Analog)
works in treating patients with metastatic prostate cancer that did not respond to hormone
therapy. Drugs used in chemotherapy, such as eribulin mesylate, work in different ways to
stop the growth of tumor cells, either by killing the cells or by stopping them from
dividing.
E7389 Versus Capecitabine in Patients With Locally Advanced or Metastatic Breast Cancer Previously Treated With Anthracyclines and Taxanes
Completed
Eisai Inc.
Phase 3
2006-09-20
The purpose of this study is to compare E7389 versus capecitabine in patients with locally
advanced or metastatic breast cancer who are refractory to the most recent chemotherapy. This
is an open-label, randomized, two-parallel arm study. Patients will be randomized to receive
either E7389 or capecitabine on a one-to-one ratio.
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.
